Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29356910 | 0.94 | CYP1A2 (0.89) | CYP1A2 | |
| SCHEMBL25192351 | 0.88 | CYP1A2 (0.78) | CYP1A2EPHX1PPARGPKMMEN1 | |
| SCHEMBL893893 | 0.86 | CYP1A2 (0.76) | CYP1A2 | |
| SCHEMBL20488928 | 0.86 | CYP1A2 (0.75) | CYP1A2EPHX1PKMMEN1HTT | |
| SCHEMBL363462 | 0.84 | CYP1A2 (0.73) | CYP1A2EPHX1PPARGPKMMEN1 | |
| SCHEMBL29874518 | 0.84 | CYP1A2 (0.73) | CYP1A2EPHX1PPARGPKMMEN1 | |
| SCHEMBL8710704 | 0.83 | CYP1A2 (0.71) | CYP1A2EPHX1PPARG | |
| SCHEMBL28238797 | 0.83 | CYP1A2 (0.71) | CYP1A2EPHX1PPARG | |
| SCHEMBL28237732 | 0.83 | CYP1A2 (0.71) | CYP1A2EPHX1PPARG | |
| SCHEMBL664978 | 0.81 | CYP1A2 (0.69) | CYP1A2EPHX1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101868439-B | 4, 5-ring liquid crystalline compound having lateral fluorine, liquid crystal composition, and liquid crystal display element | JNC CORP | 2014-02-05 | — | — | CN | disclosed |
| EP-2206695-B1 | TETRA- OR PENTA-CYCLIC LIQUID CRYSTALLINE COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC CORP (JP) | 2013-09-18 | — | — | EP | disclosed |
| US-8187494-B2 | Four- or five-ring liquid crystal compound having lateral fluorine, liquid crystal composition, and liquid crystal display device | JNC CORPORATION (JP) | 2012-05-29 | — | — | US | disclosed |
| US-20100309402-A1 | FOUR- OR FIVE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2010-12-09 | — | — | US | disclosed |
| CN-101868439-A | 4, 5-ring liquid crystalline compound having lateral fluorine, liquid crystal composition, and liquid crystal display element | CHISSO PETROCHEMICAL CORP | 2010-10-20 | — | — | CN | disclosed |
| EP-2206695-A1 | TETRA- OR PENTA-CYCLIC LIQUID CRYSTALLINE COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | Chisso Corporation (JP) | 2010-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100309402-A1 | FOUR- OR FIVE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | KIF23, HCN3, FZD7 | CYP1A2 2155/4885EPHX1 3086/4885PPARG 2977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.